Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric Jacobsen

Showing results (41-50 of 65) with videos related to

Pageof 7
Sort By:
Leukemia & Lymphoma|August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantationEleanor Taranto, Robert Redd, Erin Jeter, et al.
Blood Advances|March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W Merryman, Natasha Edwin, Robert Redd, et al.
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
Blood Advances|June 17, 2025
Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomasJosie G Ford, Min Jung Koh, Alexandra W Lenart, et al.
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 studyDai Maruyama, Eric Jacobsen, Pierluigi Porcu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2021
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyRonald S Go, Eric Jacobsen, Robert Baiocchi, et al.
Leukemia|September 28, 2019
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Pageof 7

Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Leukemia & Lymphoma|August 8, 2022
Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantationEleanor Taranto, Robert Redd, Erin Jeter, et al.
Blood Advances|March 4, 2020
Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphomaReid W Merryman, Natasha Edwin, Robert Redd, et al.
Haematologica|June 11, 2026
Outcomes in early stage peripheral T-cell lymphoma by stage, histology, and treatment patternsRobert Stuver, Zachary R Moore, Stefan K Barta, et al.
Blood|December 19, 2013
A targeted mutational landscape of angioimmunoblastic T-cell lymphomaOreofe Odejide, Oliver Weigert, Andrew A Lane, et al.
Blood Advances|June 17, 2025
Real-world evidence of duvelisib and romidepsin in relapsed/refractory peripheral and cutaneous T-cell lymphomasJosie G Ford, Min Jung Koh, Alexandra W Lenart, et al.
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 studyDai Maruyama, Eric Jacobsen, Pierluigi Porcu, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|November 15, 2021
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in OncologyRonald S Go, Eric Jacobsen, Robert Baiocchi, et al.
Leukemia|September 28, 2019
Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphomaMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
The Lancet. Oncology|November 1, 2024
Valemetostat for patients with relapsed or refractory peripheral T-cell lymphoma (VALENTINE-PTCL01): a multicentre, open-label, single-arm, phase 2 studyPier Luigi Zinzani, Koji Izutsu, Neha Mehta-Shah, et al.
Pageof 7